Dr. Reddy's Laboratories Ltd. (RDY)

38.21
0.16 0.42
NYSE : Health Technology
Prev Close 38.37
Open 38.24
Day Low/High 37.83 / 38.46
52 Wk Low/High 31.58 / 42.82
Volume 157.49K
Avg Volume 186.40K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 6.46B
EPS 1.60
P/E Ratio 23.45
Div & Yield 0.26 (0.67%)

Latest News

Dr. Reddy's Laboratories Limited To Present At The Morgan Stanley Annual Global Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The Morgan Stanley Annual Global Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) announced that the Company will be presenting at the Morgan Stanley 17 th Annual Global Healthcare Conference on Tuesday, September 10 th, 2019, in New York City.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: NYCB, RDY, VIAV Downgrades: ALXN, BGG, BTU, EOG, FFIC, GNE, HONE, IPG, KEX, LCUT, MAGS, MCFT, PCSB, UVE Initiations: ECOR Read on to get TheStreet Quant Ratings' detailed report:

Exelixis And Aurigene Enter Into Exclusive Collaboration, Option And License Agreement To Discover And Develop Novel Therapies For Cancer

Exelixis And Aurigene Enter Into Exclusive Collaboration, Option And License Agreement To Discover And Develop Novel Therapies For Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology company focused on oncology...

Dr. Reddy's Q1 FY20 Financial Results

Dr. Reddy's Q1 FY20 Financial Results

Dr. Reddy's Laboratories Ltd.

Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults

Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults

Strategic Acquisition of Tosymra™ (sumatriptan) Nasal Spray and Zembrace® SymTouch® (sumatriptan) Injection Further Expands and Diversifies Company's Portfolio

Dr. Reddy's Laboratories Announces Closure Of The Transaction To Divest ZEMBRACE® SYMTOUCH® And TOSYMRA™ To Upsher-Smith Laboratories, LLC

Dr. Reddy's Laboratories Announces Closure Of The Transaction To Divest ZEMBRACE® SYMTOUCH® And TOSYMRA™ To Upsher-Smith Laboratories, LLC

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces the closure of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the...

Dr. Reddy's To Release Q1 FY 20 Results On July 29, 2019

Dr. Reddy's To Release Q1 FY 20 Results On July 29, 2019

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces Entering Into A Definitive Agreement To Sell Its Neurology Branded Products To Upsher-Smith Laboratories, LLC

Dr. Reddy's Laboratories Announces Entering Into A Definitive Agreement To Sell Its Neurology Branded Products To Upsher-Smith Laboratories, LLC

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr.

Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan Nasal Spray) And Zembrace® SymTouch® (sumatriptan Injection)

Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan Nasal Spray) And Zembrace® SymTouch® (sumatriptan Injection)

Strategic Acquisition Diversifies Company's Portfolio and Provides New Options for Migraine Patients

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States...

An Auction House, a Chemical Maker and Other Stocks That Look Good Short

BID, TWOU, RDY, ALB and PTR all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEL, FBK, FRO, NODK, OPBK Downgrades: ALB, APYX, BHE, CREE, MEDP, NTWK, PPDF, RDY, SINO, SVM, SVT, SVVC, TPC, TPCO Initiations: CLBK, LEVL, MOR Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Q4 & FY19 Financial Results

Dr. Reddy's Q4 & FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders Or Former Shareholders To Contact The Firm Immediately

URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders Or Former Shareholders To Contact The Firm Immediately

NEW YORK, May 1, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City announces that it is investigating Dr.

Dr. Reddy's To Release Q4 And Full Year FY 19 Results On May 17, 2019

Dr. Reddy's To Release Q4 And Full Year FY 19 Results On May 17, 2019

Dr. Reddy's Laboratories Ltd.

TheStreet Quant Rating: B- (Buy)